Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
Icecure Medical (ICCM) Stock Price & Analysis
92 Followers
ICCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.52 - $1.57
Previous Close$1.04
Volume50.97K
Average Volume (3M)502.65K
Market Cap
$53.90M
Enterprise Value$41.56M
Total Cash (Recent Filing)$11.43M
Total Debt (Recent Filing)$599.00K
Price to Earnings (P/E)-3.2
Beta0.69
Next Earnings
Aug 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding45,729,684
10 Day Avg. Volume368,217
30 Day Avg. Volume502,650
Standard Deviation1.08
R-Squared0.02
Alpha0.16
Financial Highlights & Ratios
Price to Book (P/B)3.91
Price to Sales (P/S)15.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.70
Enterprise Value/Gross Profit31.97
Enterprise Value/Ebitda-5.03
Forecast
1Y Price Target
$2.97Price Target Upside177.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Icecure Medical News
PremiumCompany Announcements
IceCure’s ProSense Shows Promise in Japanese Study
PremiumCompany Announcements
IceCure Medical Announces Upcoming Shareholders Meeting
PremiumCompany Announcements
IceCure Medical Eyes FDA Approval with Promising Trial Results
Bulls Say, Bears Say
Bulls Say
Financial PerformancePreliminary revenue shows significant growth with a notable increase in the latest quarter.
Regulatory UpdateFDA reopened its request for De Novo classification for marketing authorization of its ProSense System for early-stage breast cancer in low-risk patients.
Strategic DevelopmentsManagement's plan to reduce operating expenses is set to decrease cash utilization, enhancing financial stability.
Bears Say
Earnings MissICCM reported revenue significantly below consensus and analyst estimates, with a substantial year-over-year decline.
Financial StabilityThe company may need to raise additional capital within the next 12 months, which could dilute current shareholder value.
Regulatory ChallengesThe company's De Novo application for treating early-stage, low-risk breast cancer was denied by the FDA, leading to an appeal.
---
Ownership Overview
0.00%
Insiders
<0.01% Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ICCM FAQ
What was IceCure Medical’s price range in the past 12 months?
IceCure Medical lowest stock price was $0.52 and its highest was $1.57 in the past 12 months.
What is IceCure Medical’s market cap?
Currently, no data Available
When is IceCure Medical’s upcoming earnings report date?
IceCure Medical’s upcoming earnings report date is Aug 12, 2024 which is in 84 days.
How were IceCure Medical’s earnings last quarter?
Currently, no data Available
Is IceCure Medical overvalued?
According to Wall Street analysts IceCure Medical’s price is currently Undervalued.
Does IceCure Medical pay dividends?
IceCure Medical does not currently pay dividends.
What is IceCure Medical’s EPS estimate?
IceCure Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IceCure Medical have?
IceCure Medical has 45,729,683 shares outstanding.
What happened to IceCure Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IceCure Medical?
Among the largest hedge funds holding IceCure Medical’s share is ARK Investment Management LLC. It holds IceCure Medical’s shares valued at N/A.
---
Icecure Medical Stock Smart Score
Company Description
IceCure Medical
Icecure Medical Ltd is a Israel based firm which develops and markets minimally invasive cryoablation therapies for women's health. The company provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma.
---
ICCM Stock 12 Month Forecast
Average Price Target
$2.97
▲(177.57% Upside)
Technical Analysis
Best Analysts Covering ICCM
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
+1.74%
reiterated a buy rating 2 months ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +1.74% per trade.
---